Forecasting essential childhood cancer drug need: An innovative model-based approach.
essential drugs
essential medicines
forecasting
global health
pediatric
pediatric cancer
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
15 08 2021
15 08 2021
Historique:
revised:
21
02
2021
accepted:
04
03
2021
pubmed:
13
4
2021
medline:
9
3
2022
entrez:
12
4
2021
Statut:
ppublish
Résumé
Childhood cancer outcomes in low-income and middle-income countries have not kept pace with advances in care and survival in high-income countries. A contributing factor to this survival gap is unreliable access to essential drugs. The authors created a tool (FOR On the basis of domestic public-sector price data, the projected annual cost of drugs to treat childhood cancer cases is 0.8 million US dollars in Kenya and 3.0 million US dollars in China, with average median price ratios of 0.9 and 0.1, respectively, compared with costs sourced from the Management Sciences for Health (MSH) International Medical Products Price Guide. According to the cumulative chemotherapy cost, the most expensive disease to treat is acute lymphoblastic lymphoma in Kenya, but a higher relative unit cost of methotrexate makes osteosarcoma the most expensive diagnosis to treat in China. FOR
Sections du résumé
BACKGROUND
Childhood cancer outcomes in low-income and middle-income countries have not kept pace with advances in care and survival in high-income countries. A contributing factor to this survival gap is unreliable access to essential drugs.
METHODS
The authors created a tool (FOR
RESULTS
On the basis of domestic public-sector price data, the projected annual cost of drugs to treat childhood cancer cases is 0.8 million US dollars in Kenya and 3.0 million US dollars in China, with average median price ratios of 0.9 and 0.1, respectively, compared with costs sourced from the Management Sciences for Health (MSH) International Medical Products Price Guide. According to the cumulative chemotherapy cost, the most expensive disease to treat is acute lymphoblastic lymphoma in Kenya, but a higher relative unit cost of methotrexate makes osteosarcoma the most expensive diagnosis to treat in China.
CONCLUSIONS
FOR
Substances chimiques
Antineoplastic Agents
0
Drugs, Essential
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2990-3001Informations de copyright
© 2021 American Cancer Society.
Références
Smith MA, Seibel NL, Altekruse SF, et al. Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol. 2010;28:2625-2634.
Ward ZJ, Yeh JM, Bhakta N, Frazier AL, Girardi F, Atun R. Global childhood cancer survival estimates and priority-setting: a simulation-based analysis. Lancet Oncol. 2019;20:972-983.
Rodriguez-Galindo C, Friedrich P, Alcasabas P, et al. Toward the cure of all children with cancer through collaborative efforts: pediatric oncology as a global challenge. J Clin Oncol. 2015;33:3065-3073.
Mehta PS, Wiernikowski JT, Petrilli JA, Barr RD; Working Group on Essential Medicines of the Pediatric Oncology in Developing Countries Committee of SIOP. Essential medicines for pediatric oncology in developing countries. Pediatr Blood Cancer. 2013;60:889-891.
Faruqui N, Martiniuk A, Sharma A, et al. Evaluating access to essential medicines for treating childhood cancers: a medicines availability, price and affordability study in New Delhi, India. BMJ Glob Health. 2019;4:e001379.
Tangcharoensathien V, Mills A, Palu T. Accelerating health equity: the key role of universal health coverage in the Sustainable Development Goals. BMC Med. 2015;13:101.
Schmidt H, Gostin LO, Emanuel EJ. Public health, universal health coverage, and Sustainable Development Goals: Can they coexist? Lancet. 2015;386:928-930.
United Nations General Assembly. Political Declaration of the High-level Meeting of the General Assembly on the Prevention and Control of Non-Communicable Diseases. United Nations; 2011.
Beaglehole R, Bonita R, Horton R, et al. Priority actions for the non-communicable disease crisis. Lancet. 2011;377:1438-1447.
Eggebratten T, Urman A, Mangan J, Wang CH, Suarez Saiz FJ. ChemoQuant: a novel approach to address the current chemotherapy supply problems in low resource countries [abstract]. J Clin Oncol. 2018;36(15 suppl):e18593.
Wilson BE, Jacob S, Yap ML, Ferlay J, Bray F, Barton MB. Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a population-based study. Lancet Oncol. 2019;20:769-780.
Tang B, Bodkyn C, Gupta S, Denburg AE. Access to WHO essential medicines for childhood cancer care in Trinidad and Tobago: a health system analysis of barriers and enablers. JCO Glob Oncol. 2020;6:67-79.
Yabroff KR, Lund J, Kepka D, Mariotto A. Economic burden of cancer in the United States: estimates, projections, and future research. Cancer Epidemiol Biomarkers Prev. 2011;20:2006-2014.
Ward ZJ, Yeh JM, Bhakta N, Frazier AL, Atun R. Estimating the total incidence of global childhood cancer: a simulation-based analysis. Lancet Oncol. 2019;20:483-493.
The World Bank. World Development Indicators, 2020. The World Bank; 2020.
National Cancer Institute (NCI). Surveillance, Epidemiology, and End Results (SEER) Program: Registry Data From 1973 to 2013. NCI; 2020.
Cangemi G, Reggiardo G, Barco S, et al. Prognostic value of ferritin, neuron-specific enolase, lactate dehydrogenase, and urinary and plasmatic catecholamine metabolites in children with neuroblastoma. Onco Targets Ther. 2012;5:417-423.
Bhojwani D, Howard SC, Pui CH. High-risk childhood acute lymphoblastic leukemia. Clin Lymphoma Myeloma. 2009;9(suppl 3):S222-S230.
Platzbecker U, Avvisati G, Cicconi L, et al. Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial. J Clin Oncol. 2017;35:605-612.
Poynter JN, Amatruda JF, Ross JA. Trends in incidence and survival of pediatric and adolescent patients with germ cell tumors in the United States, 1975 to 2006. Cancer. 2010;116:4882-4891.
Sanz MA, Montesinos P, Kim HT, et al. All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies. Ann Hematol. 2015;94:1347-1356.
Teachey DT, Hunger SP. Predicting relapse risk in childhood acute lymphoblastic leukaemia. Br J Haematol. 2013;162:606-620.
London WB, Moroz V, Hero B, et al. A neuroblastoma risk classification model for developing countries: a study from the International Neuroblastoma (NB) Risk Group (INRG) database [abstract]. J Clin Oncol. 2014;32(15 suppl):10030.
Howard SC, Davidson A, Luna-Fineman S, et al. A framework to develop adapted treatment regimens to manage pediatric cancer in low- and middle-income countries: the Pediatric Oncology in Developing Countries (PODC) Committee of the International Pediatric Oncology Society (SIOP). Pediatr Blood Cancer. 2017;64(suppl 5):26879.
Hessissen L, Parkes J, Amayiri N, et al. SIOP PODC adapted treatment guidelines for low grade gliomas in low and middle income settings. Pediatr Blood Cancer. 2017;64(suppl 5):26737.
Parkes J, Hendricks M, Ssenyonga P, et al. SIOP PODC adapted treatment recommendations for standard-risk medulloblastoma in low and middle income settings. Pediatr Blood Cancer. 2015;62:553-564.
Israels T, Moreira C, Scanlan T, et al. SIOP PODC: clinical guidelines for the management of children with Wilms tumour in a low income setting. Pediatr Blood Cancer. 2013;60:5-11.
Chantada G, Luna-Fineman S, Sitorus RS, et al. SIOP-PODC recommendations for graduated-intensity treatment of retinoblastoma in developing countries. Pediatr Blood Cancer. 2013;60:719-727.
Molyneux E, Davidson A, Orem J, et al. The management of children with Kaposi sarcoma in resource limited settings. Pediatr Blood Cancer. 2013;60:538-542.
Hesseling P, Israels T, Harif M, Chantada G, Molyneux E, Pediatric Oncology in Developing Countries. Practical recommendations for the management of children with endemic Burkitt lymphoma (BL) in a resource limited setting. Pediatr Blood Cancer. 2013;60:357-362.
World Health Organization (WHO). World Health Organization Model List of Essential Medicines for Children. WHO; 2017. Accessed November 9, 2019. https://www.who.int/medicines/publications/essentialmedicines/en/
World Health Organization (WHO). WHO Model List of Essential Medicine: Adults. 20th ed. WHO; 2017. Accessed September 20, 2020. https://apps.who.int/iris/bitstream/handle/10665/273826/EML-20-eng.pdf?ua=1
Hunger SP, Sung L, Howard SC. Treatment strategies and regimens of graduated intensity for childhood acute lymphoblastic leukemia in low-income countries: a proposal. Pediatr Blood Cancer. 2009;52:559-565.
United Nations Development Program (UNDP), Human Development Reports. Inequality-Adjusted Health Development Index (IHDI). UNDP; 2018. Accessed September 20, 2020. http://hdr.undp.org/en/content/inequality-adjusted-human-development-index-ihdi
Tandon A, Murrah CJL, Lauer JA, Evans DB. Measuring overall health system performance for 191 countries. Global Programme on Evidence (GPE) Discussion Paper Series: No. 30. World Health Organization; 2000.
International Association of Cancer Registries (IACR), World Health Organization (WHO). International Incidence of Childhood Cancer 3. IARC; 2019.
US Agency for International Development (USAID). STAT Compiler. The DHS Program. USAID, Demographic and Health Surveys Program; 2019. Accessed September 20, 2020. https://www.statcompiler.com/en/
Management Sciences for Health (MSH). Managing Access to Medicines and Health Technologies. MSH; 2012. Accessed September 20, 2020. https://www.msh.org/resources/international-medical-products-price-guide
World Health Organization (WHO) and Health Action International. Measuring Medicine Prices, Availability, Affordability and Price Components. 2nd ed. WHO; 2008.
The World Bank. Official Exchange Rate. The World Bank; 2020.
Creutzig U, Zimmermann M, Dworzak M, et al. Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses. Br J Haematol. 2010;149:399-409.
Parikh NS, Howard SC, Chantada G, et al. SIOP-PODC adapted risk stratification and treatment guidelines: recommendations for neuroblastoma in low- and middle-income settings. Pediatr Blood Cancer. 2015;62:1305-1316.
Canadian Agency for Drugs and Technologies in Health (CADTH). Pan-Canadian Oncology Drug Review. Final Clinical Guidance Report: Arsenic Trioxide (Trisenox) for Acute Promyelocytic Leukemia. CADTH; 2014.
Carter NH, Avery AH, Libes J, Lovvorn HN 3rd, Hansen EN. Pediatric solid tumors in resource-constrained settings: a review of available evidence on management, outcomes, and barriers to care. Children (Basel). 2018;5:143.
Stefan DC, Siemonsma F. Delay and causes of delay in the diagnosis of childhood cancer in Africa. Pediatr Blood Cancer. 2011;56:80-85.
Metzger ML, Billett A, Link MP. The impact of drug shortages on children with cancer-the example of mechlorethamine. N Engl J Med. 2012;367:2461-2463.
Gupta S, Wang C, Raetz EA, et al. Impact of asparaginase discontinuation on outcome in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. J Clin Oncol. 2020;38:1897-1905.
‘t Hoen EF, Veraldi J, Toebes B, Hogerzeil HV. Medicine procurement and the use of flexibilities in the Agreement on Trade-Related Aspects of Intellectual Property Rights, 2001-2016. Bull World Health Organ. 2018;96:185-193.
Cheema PK, Gavura S, Migus M, Godman B, Yeung L, Trudeau ME. International variability in the reimbursement of cancer drugs by publically funded drug programs. Curr Oncol. 2012;19:e165-e176.
Nguyen TA, Knight R, Roughead EE, Brooks G, Mant A. Policy options for pharmaceutical pricing and purchasing: issues for low- and middle-income countries. Health Policy Plan. 2015;30:267-280.
Denburg A, Arora B, Arora RS, et al. Access to essential medicines for children with cancer: a joint SIOP-CCI position statement. Lancet Oncol. 2017;18:20-22.
Leung CYW, Cheung MC, Charbonneau LF, Prica A, Ng P, Chan KKW. Financial impact of cancer drug wastage and potential cost savings from mitigation strategies. J Oncol Pract. 2017;13:e646-e652.